Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.

Medicina (Kaunas) · 2022 · PMC9146481 · PMID 35630016

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

With mature overall survival (OS) results pending, a slight trend favoring pembrolizumab was observed; in addition, pCR was significantly higher in TNBC patients receiving pembrolizumab plus neoadjuvant chemotherapy than among those receiving placebo—chemotherapy [ 17 ].

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.